A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma
Authors
Keywords
Oesophago-gastric cancer, Adenocarcinoma, Bortezomib, Chemotherapy
Journal
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 2, Pages 250-260
Publisher
Springer Nature
Online
2013-05-10
DOI
10.1007/s10637-013-9970-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NF-κB and the link between inflammation and cancer
- (2012) Joseph A. DiDonato et al. IMMUNOLOGICAL REVIEWS
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- (2010) Manish A. Shah et al. INVESTIGATIONAL NEW DRUGS
- Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation
- (2010) Chunyang Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)
- (2010) Aminah Jatoi et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- NF-κB addiction and its role in cancer: ‘one size does not fit all’
- (2010) M M Chaturvedi et al. ONCOGENE
- Phase I Study of Capecitabine and Oxaliplatin in Combination With the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors
- (2009) Steven J. Cohen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells
- (2009) T. Hideshima et al. BLOOD
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
- (2008) S Rao et al. BRITISH JOURNAL OF CANCER
- A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer
- (2008) Noelle K. LoConte et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours
- (2008) S. Cresta et al. EUROPEAN JOURNAL OF CANCER
- The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study
- (2008) Angela M. Davies et al. Journal of Thoracic Oncology
- Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells
- (2008) S. Markovina et al. MOLECULAR CANCER RESEARCH
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ubiquitin-proteasome pathway and enhanced activity of NF-κB in gastric carcinoma
- (2007) Lingfei Wu et al. JOURNAL OF SURGICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation